Health Economics›Esophageal squamous cell carcinoma›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Esophageal squamous cell carcinoma · 25 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6 and Pembrolizumab Variant #01	—	R 172 058	42d	—	—	~18	~R 2 967 706 indirect	—
Cisplatin and Paclitaxel (TP) and Pembrolizumab Variant #01	—	R 83 588	21d	—	~26.4 mo	~35	~R 2 879 160 PFS proxy · indirect	2
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 83 223	21d	—	~12.5 mo	~35	~R 2 876 965 PFS proxy · indirect	4
Cisplatin and Fluorouracil (CF) and Cetuximab Variant #03	—	R 78 877	29d	~5.5 mo	~10.9 mo	~6	~R 260 671 PFS proxy · indirect	5
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	12.7 mo	9	R 707 538 PFS proxy	1
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	~24.0 mo	—	~3	~R 9 556 PFS proxy · indirect	1
Cisplatin and Paclitaxel (TP) and Sintilimab Variant #01 Partial	—	R 3 055	28d	—	17.2 mo	26	R 10 490 PFS proxy	1
Oxaliplatin, Paclitaxel, Tislelizumab Variant #01 Partial	—	R 2 888	21d	—	17.2 mo	2	R 5 777 PFS proxy	—
Oxaliplatin and Paclitaxel Variant #01	—	R 2 888	21d	—	10.6 mo	2	R 5 777 PFS proxy	—
CapeOx Variant #01	—	R 2 620	21d	—	10.6 mo	2	R 5 240 PFS proxy	—
Fluorouracil and Oxaliplatin (FUOX) and Tislelizumab Variant #01 Partial	—	R 2 188	21d	—	17.2 mo	2	R 4 376 PFS proxy	—
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 783	28d	5.4 mo	11.1 mo	3	R 5 350 PFS proxy	7
Cisplatin and Paclitaxel (TP) and Toripalimab Variant #02 Partial	—	R 1 748	21d	—	17.0 mo	7	R 10 490 PFS proxy	1
Cisplatin and Paclitaxel (TP) and Tislelizumab Variant #01 Partial	—	R 1 748	21d	—	17.2 mo	2	R 3 497 PFS proxy	—
Cisplatin and Paclitaxel (TP) and Camrelizumab Variant #02 Partial	—	R 1 748	21d	6.9 mo	15.5 mo	7	R 10 490 PFS proxy	3
FUOX Variant #01	—	R 1 629	14d	—	10.6 mo	18	R 29 321 PFS proxy	—
Capecitabine and Cisplatin (CX) and Tislelizumab Variant #01 Partial	—	R 1 480	21d	—	17.2 mo	2	R 2 960 PFS proxy	—
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 480	21d	—	10.6 mo	6	R 8 879 PFS proxy	—
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	5.6 mo	11.1 mo	7	R 9 204 PFS proxy	5
Etoposide monotherapy Variant #01	—	R 1 231	28d	—	—	~6	~R 7 386 indirect	—
Cisplatin and Fluorouracil (CF) and Nivolumab Variant #01 Partial	—	R 1 048	28d	—	13.2 mo	27	R 28 292 PFS proxy	1
Cisplatin and Fluorouracil (CF) and Sintilimab Variant #01 Partial	—	R 1 048	28d	—	17.2 mo	26	R 6 287 PFS proxy	1
Cisplatin and Fluorouracil (CF) and Tislelizumab Variant #01 Partial	—	R 1 048	21d	—	17.2 mo	2	R 2 096 PFS proxy	—
Cisplatin and Fluorouracil (CF) and Sugemalimab Variant #01 Partial	—	R 927	21d	6.2 mo	15.3 mo	35	R 5 559 PFS proxy	2
Capecitabine and Oxaliplatin (CapeOx) and Tislelizumab Partial	—	—	—	—	17.2 mo	—	—	—

25 of 25 regimens shown